Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112

Autor: Kristian Thidemann Andersen, Maja Hinge, Erik Kay Segel, Tina Ormstrup, Paw Holdgaard, Henrik Boel-Jørgensen, Niels Pallisgaard, Gitte Birk Kerndrup, Torben Plesner

Publikováno v: Andersen, K T, Hinge, M, Segel, E K, Ormstrup, T, Holdgaard, P, Boel-Jørgensen, H, Pallisgaard, N, Kerndrup, G B & Plesner, T 2015, ' Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112 ', 15th International Myeloma Workshop (IMW), Rome, Italy, 23/09/2015-26/09/2015 .
University of Southern Denmark

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::577207e5b8317b892b169bf8e4254164
https://portal.findresearcher.sdu.dk/da/publications/b9c9fc5a-83df-46a3-8a8a-c529fa19cda5